KR930013112A - 바이러스성 항원을 이용한 특이적 면역원의 발현 - Google Patents
바이러스성 항원을 이용한 특이적 면역원의 발현 Download PDFInfo
- Publication number
- KR930013112A KR930013112A KR1019920023656A KR920023656A KR930013112A KR 930013112 A KR930013112 A KR 930013112A KR 1019920023656 A KR1019920023656 A KR 1019920023656A KR 920023656 A KR920023656 A KR 920023656A KR 930013112 A KR930013112 A KR 930013112A
- Authority
- KR
- South Korea
- Prior art keywords
- epitope
- polypeptide
- protein
- vaccine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 title claims abstract 7
- 102000036639 antigens Human genes 0.000 title claims abstract 7
- 108091007433 antigens Proteins 0.000 title claims abstract 7
- 230000003612 virological effect Effects 0.000 title claims 4
- 241000712431 Influenza A virus Species 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 12
- 230000000890 antigenic effect Effects 0.000 claims abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 11
- 239000002773 nucleotide Substances 0.000 claims abstract 10
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 10
- 229960005486 vaccine Drugs 0.000 claims abstract 9
- 239000012634 fragment Substances 0.000 claims abstract 7
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract 5
- 239000013604 expression vector Substances 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 239000012636 effector Substances 0.000 claims 6
- 102200020671 rs121912988 Human genes 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 102000018697 Membrane Proteins Human genes 0.000 claims 4
- 108010077805 Bacterial Proteins Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 102220350531 c.80A>G Human genes 0.000 claims 3
- 102200061298 rs1064795967 Human genes 0.000 claims 3
- 102220323264 rs777883490 Human genes 0.000 claims 3
- 229940037003 alum Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical group OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims 1
- 229960005225 mifamurtide Drugs 0.000 claims 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 102400000368 Surface protein Human genes 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 101150039660 HA gene Proteins 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80510591A | 1991-12-11 | 1991-12-11 | |
| US07/805,105 | 1991-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930013112A true KR930013112A (ko) | 1993-07-21 |
Family
ID=25190685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920023656A Withdrawn KR930013112A (ko) | 1991-12-11 | 1992-12-09 | 바이러스성 항원을 이용한 특이적 면역원의 발현 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5591823A (enExample) |
| EP (1) | EP0546787A3 (enExample) |
| JP (1) | JPH05262667A (enExample) |
| KR (1) | KR930013112A (enExample) |
| CN (1) | CN1073878A (enExample) |
| AU (1) | AU2981992A (enExample) |
| BR (1) | BR9204978A (enExample) |
| CA (1) | CA2084180A1 (enExample) |
| CZ (1) | CZ362692A3 (enExample) |
| FI (1) | FI925590A7 (enExample) |
| HU (2) | HUT65366A (enExample) |
| IL (1) | IL103928A0 (enExample) |
| MX (1) | MX9207113A (enExample) |
| NO (1) | NO924780L (enExample) |
| SK (1) | SK362692A3 (enExample) |
| TW (1) | TW239162B (enExample) |
| ZA (1) | ZA929355B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180115717A (ko) * | 2016-02-03 | 2018-10-23 | 씨지 디스커버리, 인코포레이티드 | 이종 에피토프 및/또는 성숙 절단 부위를 갖는 인플루엔자 헤마글루티닌 조성물 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633929B1 (en) * | 1992-04-01 | 2004-03-03 | The Rockefeller University | METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS |
| DE69332485T2 (de) * | 1992-08-11 | 2003-11-13 | The President And Fellows Of Harvard College, Cambridge | Immunmodulierende peptide |
| WO1995007099A1 (en) * | 1993-09-09 | 1995-03-16 | The Nisshin Oil Mills, Ltd. | Vaccine and process for producing the same |
| EP2374894B1 (en) * | 1993-09-13 | 2014-09-17 | Protein Sciences Corporation | A method for producing influenza hemagglutinin multivalent vaccines |
| US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| EP1275726B1 (en) * | 1995-05-26 | 2008-02-20 | Mg-Pmc, L.L.C. | A method for producing influenza hemagglutinin multivalent vaccines |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| WO1998048834A1 (en) * | 1997-04-30 | 1998-11-05 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents |
| DE69840739D1 (de) | 1997-10-27 | 2009-05-28 | Merix Bioscience Inc | Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen |
| JP2002504322A (ja) | 1998-02-20 | 2002-02-12 | ザ ロックフェラー ユニバーシティー | 樹状細胞に対するアポトーシス細胞介在抗原提示 |
| WO2002026252A1 (en) * | 2000-08-10 | 2002-04-04 | Tsinghua University | A vaccine for influenza virus and its preparation |
| KR100836520B1 (ko) | 2000-09-11 | 2008-06-12 | 다우 글로벌 테크놀로지스 인크. | 무공압 주행 타이어 지지부 |
| US20040203084A1 (en) * | 2003-04-10 | 2004-10-14 | Doug Levinson | Profiling conformational variants, antibody compositions and methods of using the same |
| CA2610667A1 (en) * | 2005-06-01 | 2006-12-07 | Variation Biotechnologies Inc. | Peptide-based influenza vaccine formulation |
| CA2637600A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CA2976814C (en) * | 2007-08-27 | 2022-12-13 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods for treating influenza |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| WO2010047062A1 (en) | 2008-10-22 | 2010-04-29 | Oncotherapy Science, Inc. | Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| CN101708442B (zh) * | 2009-09-04 | 2011-08-24 | 山东中惠仪器有限公司 | 全自动标准气体配制装置 |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339504A3 (en) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
| US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| EP0492920A1 (en) * | 1990-12-24 | 1992-07-01 | Merck & Co. Inc. | Chimaeric influenza-HIV vaccine |
-
1992
- 1992-11-30 IL IL103928A patent/IL103928A0/xx unknown
- 1992-11-30 CA CA002084180A patent/CA2084180A1/en not_active Abandoned
- 1992-12-01 JP JP4321768A patent/JPH05262667A/ja active Pending
- 1992-12-02 AU AU29819/92A patent/AU2981992A/en not_active Abandoned
- 1992-12-02 ZA ZA929355A patent/ZA929355B/xx unknown
- 1992-12-07 EP EP19920311146 patent/EP0546787A3/en not_active Withdrawn
- 1992-12-07 TW TW081109778A patent/TW239162B/zh active
- 1992-12-09 KR KR1019920023656A patent/KR930013112A/ko not_active Withdrawn
- 1992-12-09 MX MX9207113A patent/MX9207113A/es unknown
- 1992-12-09 FI FI925590A patent/FI925590A7/fi not_active Application Discontinuation
- 1992-12-10 CN CN92113703A patent/CN1073878A/zh active Pending
- 1992-12-10 CZ CS923626A patent/CZ362692A3/cs unknown
- 1992-12-10 BR BR9204978A patent/BR9204978A/pt not_active Application Discontinuation
- 1992-12-10 SK SK3626-92A patent/SK362692A3/sk unknown
- 1992-12-10 NO NO92924780A patent/NO924780L/no unknown
- 1992-12-11 HU HU9203931A patent/HUT65366A/hu unknown
-
1993
- 1993-12-17 US US08/169,813 patent/US5591823A/en not_active Expired - Lifetime
-
1995
- 1995-06-27 HU HU95P/P00456P patent/HU211548A9/hu unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180115717A (ko) * | 2016-02-03 | 2018-10-23 | 씨지 디스커버리, 인코포레이티드 | 이종 에피토프 및/또는 성숙 절단 부위를 갖는 인플루엔자 헤마글루티닌 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1073878A (zh) | 1993-07-07 |
| CZ362692A3 (en) | 1994-02-16 |
| NO924780D0 (no) | 1992-12-10 |
| NO924780L (no) | 1993-06-14 |
| JPH05262667A (ja) | 1993-10-12 |
| ZA929355B (en) | 1994-06-02 |
| EP0546787A3 (en) | 1994-06-01 |
| FI925590L (fi) | 1993-06-12 |
| MX9207113A (es) | 1994-05-31 |
| SK362692A3 (en) | 1995-11-08 |
| HU211548A9 (en) | 1995-12-28 |
| AU2981992A (en) | 1993-06-17 |
| HUT65366A (en) | 1994-05-02 |
| BR9204978A (pt) | 1993-06-15 |
| FI925590A0 (fi) | 1992-12-09 |
| TW239162B (enExample) | 1995-01-21 |
| EP0546787A2 (en) | 1993-06-16 |
| IL103928A0 (en) | 1993-04-04 |
| FI925590A7 (fi) | 1993-06-12 |
| US5591823A (en) | 1997-01-07 |
| HU9203931D0 (en) | 1993-04-28 |
| CA2084180A1 (en) | 1993-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930013112A (ko) | 바이러스성 항원을 이용한 특이적 면역원의 발현 | |
| JP5814331B2 (ja) | Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法 | |
| AU2007202739B2 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| KR910012233A (ko) | 칠면조의 재조합 포진바이러스와 그것에서 유도한 생존상태의 벡터 백신류 | |
| KR960703136A (ko) | 탠덤 합성 hiv-1 펩티드들 | |
| AU2001282706A1 (en) | HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines | |
| KR20130041185A (ko) | 디자이너(designer) 펩티드-기반 pcv2 백신 | |
| AU2001286336B2 (en) | HIV peptides from Tat, Rev and Wef conserved and their application as E.G. vaccine components | |
| US7056519B2 (en) | Methods for inducing HIV-neutralizing antibodies | |
| CN115340609A (zh) | 一种口蹄疫病毒多抗原表位融合蛋白、蛋白笼纳米颗粒及其制备方法 | |
| JP2656521B2 (ja) | ネコ白血病ウイルス抗原の製造法と用途 | |
| JPS63254983A (ja) | エイズの病原であるウイルスのｐ２５蛋白質をコードするウイルスベクター及び組換ＤＮＡ、感染された細胞培養物、得られる蛋白質、ワクチン及び得られる抗体 | |
| AU2006235987B2 (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
| Wong | The development of the Pseudomonas aeruginosa outer membrane protein OprF as a presentation vector for foreign antigenic determinants | |
| HK1114395A (en) | Hiv peptides from conserved regions in gag p17 and p24 and their application in e.g. vaccines | |
| RU92004487A (ru) | Днк, полипептид, вакцина, вектор, микроорганизм, клетка насекомого, реагент, способы лечения и профилактики, способ обнаружения антигенов | |
| WO2001029177A2 (en) | Hiv-1 subtype d peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19921209 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |